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between quality indicators and hard outcomes were tested using Cox 
regression adjusting for confounding, reporting hazard ratios (HR) 
with 95% confidence intervals.
Results: Lipid and albuminuria-lowering treatment status were asso-
ciated with a lower risk of the composite outcome (HR = 0.77 [0.67, 
0.88]; HR = 0.75 [0.59, 0.94]). Glucose-lowering treatment status 
was associated with a lower risk of the composite outcome only in 
patients with an elevated HbA1c level (HR = 0.72 [0.56, 0.93]). 
Blood pressure–lowering treatment status was not associated with a 
risk of the composite outcome. Treatment intensification with glu-
cose lowering but not with lipid-, blood pressure–, and albuminuria-
lowering drugs was also associated with a lower risk of the composite 
outcome (HR = 0.73 [0.60, 0.89]).
Conclusion: Treatment quality indicators measuring lipid- and albu-
minuria-lowering treatment status are valid quality measures because 
they predict a lower risk of cardiovascular events and mortality in 
patients with diabetes. The quality indicator measuring glucose-
lowering treatment status should only be used for restricted popula-
tions with elevated HbA1c levels. Intriguingly, the tested indicators 
measuring blood pressure–lowering treatment status and treatment 
intensification with lipid-, blood pressure–, and albuminuria-lower-
ing drugs did not predict patient outcomes. These results question 
whether all of the currently used and proposed treatment indicators 
are valid to judge health care and economics.
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Introduction: The identification of novel genes or cellular pathways 
that are involved in pancreatic β -cell function, and the development 
of reliable probes for the in vivo imaging of β cells are key challenges 
of the current diabetes treatment. Furthermore, the discovery and the 
validation of biomarkers that are predictive for the progression of 
glycemic deterioration and treatment response to current standard 
therapies or for the development of diabetic macro- and microvas-
cular complications will lead to more effective and safer treatment 
of diabetes by patient stratification in a personalized medicines 
approach of their treatment.
Patients (or Materials) and Methods: The 3 diabetes projects of 
the Innovative Medicines Initiative (IMI)—IMIDIA, SUMMIT, and 
DIRECT—are focusing on different stages of diabetes development. 
While the focus of IMIDIA is the function of the pancreatic β cell and 
its in vivo imaging, the key aspects of DIRECT and SUMMIT are the 
identification and validation of biomarkers predictive for progression 
of diabetes and treatment response, and for the development of late 
stage complications during disease progression. These 3 consortia 
form the IMI Diabetes Platform.
Results: In IMIDIA, launched on February 1, 2010, twelve aca-
demic institutions, 8 Pharma partners, and 1 small and medium-sized 
enterprise (SME) are working together to elucidate novel pathways 
that improve β -cell function and to identify diagnostic biomarkers 
for treatment monitoring in diabetes. The 5-year project addresses 
key bottlenecks in the development of β -cell–focused therapies. The 
DIRECT consortium consisting of 21 academic institutions and 4 
Pharma partners addresses the personalized medicines approach in 
type 2 diabetes patients. The focus of the consortium is the identifica-
tion of surrogate markers that can be used for patient stratification 
according to glycemic deterioration of patients at high risk for dia-
betes or early onset of diabetes and makers predictive for response to 
current standard therapies of type 2 diabetes. DIRECT was launched 
on February 1, 2012. In SUMMIT, the joint research of 19 academic 
institutions, 6 Pharma partners, and 1 SME addresses the urgent 
need for novel treatments of diabetic complications beyond glucose-
lowering therapies. The key aspect of the consortium is the identi-
fication and validation of surrogate markers for the development 
of micro- and macrovascular complications during progression of 
diabetes. The project was launched on November 1, 2009.
Conclusion: Each single participant cannot undertake this holistic 
approach of the IMI Diabetes Platform alone. The close collaboration 
between expert institutes for diabetes research and clinical devel-
opment is required to achieve the ambitious goals of the diabetes 
consortia.
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Introduction: Patients on antiplatelet therapy have a higher incidence 
of bleeding complications and reversal of antiplatelet drug effects is 
an important issue at trauma or emergency departments. For old 
and conventional anticoagulants, reversal strategies are established. 
However, there is no experience or recommendation how to antago-
nize the reversible and highly effective P2Y12-inhibitor ticagrelor 
and how to restore platelet function after ticagrelor dosing. The aim 
of the study was to describe an ex vivo model to reverse the effects 
of ticagrelor and to estimate the optimal quantity of platelet transfu-
sions required to normalize platelet aggregation.
Patients (or Materials) and Methods: To normalize platelet aggrega-
tion, increasing amounts of autologous platelet-rich plasma (PRP) 
were added ex vivo to hirudin-anticoagulated blood which was 
obtained 3 hours after the administration of ticagrelor, by spiking 
PRP into blood at ratios of 1:10, 1:5, and 1:3. Platelet aggrega-
tion was assessed by whole blood multiple electrode aggregometry 
(MEA; Multiplate®). For interpretation of aggregation, we defined 
a cutoff level of 40 A.U. as the lower limit of the range. Volunteers 
above this level were considered to exhibit normal platelet reactivity. 
Nonparametric tests were used and statistical comparisons were per-
formed with the Friedman ANOVA, and the Wilcoxon test for post 
hoc comparisons. A 2-tailed P value < 0.05 was considered significant.
Results: The strategy to reverse the effect of ticagrelor was tested 
in 20 healthy volunteers. A clear dose-response was obtained after 
spiking whole blood with increasing amounts of PRP. After addition 
of PRP at a ratio of 1:10, platelet aggregation increased to 31 ± 14 
A.U. When assuming that 1 apheresis platelet concentrate (200 mL) 
typically contains a minimum of 2 × 1011 platelets, the ratio of 
1:10 corresponds to 0.5 unit of apheresis platelet concentrates. A 
ratio of 1:5—equivalent to 1 unit of platelet concentrates—increased 
ADP induced platelet aggregation to 41±14 A.U. Platelet aggregation 
increased further to 48±18 A.U. following the addition of PRP at a 
ratio of 1:3, which corresponds to 1.5 units of platelet concentrates. 
All comparisons were significant at P < 0.01.
Conclusion: Platelets dose-dependently improve ex vivo platelet 
aggregation of subjects after a loading dose of 180 mg of ticagrelor. 
It is estimated that > 2 units of apheresis platelet concentrates will be 
necessary to completely restore baseline platelet aggregation in the 
majority of patients. Point-of-care platelet function tests may be suit-
able tools to verify this concept in emergency patients and to estimate 
the extent of the reversal and de-risk on an individual patient’s level.
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Introduction and Background: IL-17 pathway is being clinically 
targeted in immune-mediated diseases, most of which are associated 
with a significant cardiovascular risk. We investigated the relation-
ship between serum levels of IL-17 and the risk of cardiovascular 
events in patients with acute myocardial infarction.
Patients (or Materials) and Methods: We used data from patients 
enrolled in the prospective, multicenter French registry of acute 
ST elevation or non–ST-elevation myocardial Infarction (Fast-MI, 
NCT00673036). Of the 374 centers in France that treated patients 
with acute MI, 223 (60%) participated in the registry. Among these, 
100 centers recruited 1029 patients who contributed to a serum bank. 
Their baseline characteristics were comparable to the overall popu-
lation of the registry. Written informed consent was provided by 
each patient. More than 99% of patients were Caucasian. Two-year 
follow-up was > 98% complete.
Results: Serum levels of IL-17 were associated with the risk of all-
cause death and recurrent MI at 2 years, with levels of IL-17 below 
the median indicative of a worse outcome. The impact of IL-17 
remained significant after adjustment for known cardiovascular risk 
factors, CRP, and treatments including statins: hazard ratio (HR) = 
1.40 (1.03–1.91); P = 0.03.IL-17 inhibited mononuclear cell adhe-
sion to endothelium and reduced endothelial VCAM-1 expression. 
Patients with low (below the median) IL-17 levels and high (above 
the median) soluble VCAM-1 (sVCAM-1) levels were at particularly 
increased risk of death and MI: adjusted HR = 2.22 (1.32–3.75) 
compared with the high IL-17/low sVCAM-1 group (P = 0.002).
Conclusion: Low serum levels of IL-17 are associated with a higher risk 
of major cardiovascular events in Caucasian patients with acute MI. 
Our results raise possible concern about the use of inhibitors of IL-17 
pathway in clinical settings associated with a high cardiovascular risk.
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Introduction: Investigations based on quantitative sensory testing 
have consistently evidenced allodynia in FMS patients involving both 
spinal and supraspinal pain regulatory systems. Functional imaging 
studies have demonstrated enhanced neural activities in pain related 
brain areas as well as impairment of pain inhibition in the descending 
nociceptive regulatory system. Higher state of excitability of spinal 
nociceptive neurons as evidenced by lowered nociceptive flexion 
reflex R-III (NFR) threshold was reported for FMS patients. The NFR 
procedure has been shown to be a valuable tool to evaluate pharma-
cologically active therapeutic agents at the spinal level. Serotonin-
noradrenaline reuptake inhibitors have been shown to reduce pain 
in fibromyalgia syndrome patients possibly through descending 
monoaminergic pain pathways modulation. This randomized dou-
ble- blind, placebo-controlled trial assessed the pharmacodynamic 
activity of the dual-reuptake inhibitor milnacipran (MLN) at the 
spinal level by means of the objective spinal NFR.
Patients (or Materials) and Methods: Seven-week exposure (100, 
150, 200 mg/d) in female fibromyalgia patients. Evaluation consisted 
of extensive quantitative sensory testing, including determination of 
the nociceptive flexion reflex threshold (NFR), self-reported standard 
questionnaires investigating pain: visual analog scales; fibromyal-
gia impact, health-related quality of life, depression, and anxiety 
questionnaires as well as and Patient’s Global Impression of Change 
(PGIC). Analysis of covariance adjusted for baseline value was used 
for all end points.
Results: Seventy-seven (39 placebo, 38 milnacipran all doses) of 80 
randomized patients were available for analysis. The absence of influ-
ence of MLN (any dose) on the NFR surprisingly contrasted with the 
dose-dependent analgesic effect observed in MLN-treated patients 
with an adjusted change difference of –18.4 mm (–30.9; –5.8) in 
pain reduction between placebo and the maximum dosage (200 mg) 
MLN groups (P = 0.02). Unchanged depression and anxiety scores 
confirmed the predominant selectivity of the analgesic effect of MLN 
on nociceptive pain pathway. Self-reported questionnaires consist-
ently reflected the positive effects of MLN on quality of life and psy-
chological well-being. Odds ratio 5.1 for PGIC responders (ie, much/
very much improved) was significantly in favor of MLN (P = 0.04).
Conclusion: Milnacipran has a predominantly supraspinal analgesic 
effect as evidenced by the significant clinical benefits and the absence 
of changes in the nociceptive spinal reflex threshold. Higher dose 
was associated with higher pain reduction. Reported analgesia was 
independent of patients’ emotional status.
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